Drugs for Eosinophilic Gastroenteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 114)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Budesonide |
Approved |
Phase 4 |
|
51333-22-3 |
63006 5281004 |
Synonyms:
(11b,16a)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11β,16α)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
AC-4697
B 7777
B7777_SIGMA
Bidien
Bio-0010
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Budecort Inhaler
Budenofalk
Budeson
Budesónida
budesonide
Budesonide
Budesonide (JAN/USAN/INN)
Budesonide [USAN:INN:BAN:JAN]
Budesonide Easyhaler
Budesonide MMX
Budesonide, (R)-isomer
Budesonide, (S)-isomer
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
Cortivent
CPD000058337
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
Entocort
Entocort EC
Entocort EC (TN)
EU-0100174
Giona Easyhaler
HMS1569H17
|
HMS1921I22
HMS2094I13
HMS501H17
Horacort
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
Lopac0_000174
LS-187734
LS-7235
MAP-0010
Micronyl
Miflonide
MLS000028507
MLS001077323
MLS002207112
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick_840
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort turbuhaler
Pulmicort Turbuhaler
Respules
Rhinocort
Rhinocort alpha
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S1286_Selleck
S-1320
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
ST51039033
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Unit dose budesonide
ZINC03938751
ZINC04097286
|
|
2 |
|
Omeprazole |
Approved, Investigational, Vet_approved |
Phase 4 |
|
73590-58-6 |
4594 |
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(S)-(-)-Omeprazole
(S)-Omeprazole
119141-89-8
131959-78-9
172964-80-6
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
2,3,5-Trimethylpyridine/Omeprazole
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
73590-58-6
AC1L1IIJ
AC-401
AGI-010
AKOS005066653
Antra
Antra mups
Antra MUPS
Audazol
Aulcer
AULCER
Axagon
Belmazol
BIDD:GT0189
Bio-0888
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
C07324
CAS-73590-58-6
CCRIS 7099
Ceprandal
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CPD000058847
D00455
Danlox
DB00338
DB00736
Demeprazol
Desec
Dizprazol
DM-3458
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
esomeprazol
Esomeprazole
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168-68
H168/68
H-168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
Indurgan
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
LS-7629
Lucen
Magnesium, omeprazole
Maybridge4_002645
Mepral
Miol
Miracid
MLS000069373
MLS001076112
MLS001424148
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
Mopral
Morecon
NCGC00016925-01
NCGC00016925-02
|
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
omeprazole
Omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazole pellets
Omeprazole sodium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
OMP
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Prazentol
Prazidec
Prazolit
Prestwick_808
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prilosec
Prilosec (TN)
Prilosec otc
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
Sanamidol
Secrepina
SMR000058847
Sodium, omeprazole
SPBio_002306
STK623746
Tedec ulceral
Tedec Ulceral
TL8005099
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
UNII-KG60484QX9
UPCMLD-DP075
UPCMLD-DP075:001
Victrix
Zefxon
Zegerid
Zepral
Zimor
Zoltum
|
|
3 |
|
Fluticasone |
Approved, Experimental |
Phase 4 |
|
90566-53-3 |
62924 |
Synonyms:
90566-53-3
AC1NSJZT
AC-456
BIDD:GT0819
C07815
CHEMBL1201396
CID5311101
D07981
Fluticaps
|
Fluticaps (TN)
Fluticason
Fluticasona
fluticasone
Fluticasone
Fluticasone (INN)
Fluticasonum
MolPort-006-666-449
S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
|
|
4 |
|
Citalopram |
Approved |
Phase 4 |
|
59729-33-8 |
2771 |
Synonyms:
[3H]Citalopram
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
Bonitrile
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
C07572
C20H21FN2O
Celapram
Celexa
Celius
CHEBI:3723
CHEMBL549
Ciazil
CID2771
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
citalopram
Citalopram
Citalopram (USP/INN)
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopram Hydrobromide
Citalopramum
Citalopramum [INN-Latin]
|
Citol
Citopam
Citox
Citrol
CPD000465669
Cytalopram
D07704
Dalsan
DB00215
EINECS 261-891-1
Elopram
Escitalopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
Lexapro
Lopac0_000258
LS-84327
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
Seropram
ST069372
STL058639
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
|
|
5 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
6 |
|
Hormones |
|
Phase 4 |
|
|
|
7 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
8 |
|
Soy Bean |
|
Phase 4 |
|
|
|
9 |
|
Cromolyn Sodium |
|
Phase 4 |
|
|
|
10 |
|
Olive |
|
Phase 4 |
|
|
|
11 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
12 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
13 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
14 |
|
Antacids |
|
Phase 4 |
|
|
|
15 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
16 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
17 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
18 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
19 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
20 |
|
Proton Pump Inhibitors |
|
Phase 4 |
|
|
|
21 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
22 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
23 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
24 |
|
Serotonin Uptake Inhibitors |
|
Phase 4 |
|
|
|
25 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 4 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
|
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
Serotonine
sérotonine
thrombocytin
Thrombocytin
thrombotonin
Thrombotonin
|
|
26 |
|
Reslizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
241473-69-8 |
|
Synonyms:
|
27 |
|
Esomeprazole |
Approved, Investigational |
Phase 2, Phase 3 |
|
161796-78-7, 119141-88-7, 161973-10-0 |
9568614 4594 |
Synonyms:
( -)-Omeprazole
(-)-omeprazole
(−)-omeprazole
(-)-Omeprazole
(-)-Omeprazole magnesium
(S)-(−)-omeprazole
(S)-(-)-Omeprazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
(s)-omeprazole
(S)-omeprazole
(S)-Omeprazole
(S)-Omeprazole magnesium
119141-88-7
119141-89-8
131959-78-9
161973-10-0
172964-80-6
193469-77-1
1H-Benzimidazole, 5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, magnesium salt, trihydrate
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
202742-32-3
217087-09-7
302841-07-2
320416-93-1
326602-80-6
371759-50-1
372519-57-8
376628-34-1
5-methoxy-1H-1,3-benzimidazol-2-yl (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl sulfoxide
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole, magnesium salt (2:1), trihydrate
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
6-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
73590-58-6
95382-33-5
AC1L1IIJ
AC1L2XM7
AC1L2XMA
AC1NSJYQ
AC-401
AC-402
AGI-010
AKOS005066653
Alenia
Antra
Antra MUPS
AstraZeneca brand OF esomeprazole magnesium
Audazol
AULCER
Axagon
Belmazol
BIDD:GT0020
BIDD:GT0189
Bio-0888
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
C07324
CAS-73590-58-6
CCRIS 7099
Ceprandal
CHEBI:50275
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID130564
CID130565
CID4594
CID9568613
CID9568614
CID9579578
CPD000058847
D00455
D01984
D05259
D07917
D-961H
Danlox
DB00338
DB00736
Demeprazol
Desec
Dizprazol
DM-3458
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
Escz
Esofag
esomeprazol
Esomeprazol
esomeprazole
Esomeprazole
Ésoméprazole
Esomeprazole (INN)
Esomeprazole [INN:BAN]
Esomeprazole magnesium
Esomeprazole magnesium (USAN)
Esomeprazole magnesium hydrate
Esomeprazole magnesium hydrate (JAN)
Esomeprazole magnesium trihydrate
Esomeprazole potassium
Esomeprazole sodium
Esomeprazole Sodium
Esomeprazole strontium
Esomeprazole strontium anhydrous
esomeprazolum
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168-68
H 199/18
H168/68
H-168/68
H199/18
H-199/18
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
I06-1976
IDI1_032523
InChI=1/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20
Indurgan
|
Inexium paranova
Inexium paranova (TN)
Inhibitron
Inhipump
KS-1054
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
LS-181810
LS-185188
LS-7629
Lucen
magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide trihydrate
Maybridge4_002645
Mepral
Miol
Miracid
MLS000069373
MLS001076112
MLS001165732
MLS001424148
MolPort-002-885-822
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
MolPort-005-940-841
MolPort-005-943-880
Mopral
Morecon
N Bis (1H-Benzimidazole,5-methoxy-2-[(S)-[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl]-)
NCGC00016925-01
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium (TN)
Nexium Control
Nexium IV
Nexium, Esomeprazole magnesium
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazole S-form
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick_808
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prilosec
Prilosec (TN)
Prilosec OTC
Prilosec OTC (TN)
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
S1743_Selleck
SAM001246900
SAN-15
Sanamidol
Secrepina
SMR000058847
SMR000550477
SPBio_002306
ST51053319
STK623746
Strontium, esomeprazole
Tedec Ulceral
TL8005099
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
UNII-KG60484QX9
UNII-N3PA6559FT
UNII-R6DXU4WAY9
UPCMLD-DP075
UPCMLD-DP075:001
Victrix
Zefxon
Zegerid
Zepral
Zimor
ZINC04693574
ZINC04693575
Zoltum
|
|
28 |
|
Benralizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1044511-01-4 |
|
29 |
|
Histamine |
Approved, Investigational |
Phase 3 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
5-imidazoleethylamine
5-Imidazoleethylamine
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
|
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Ceplene
Dihydrochloride, histamine
Eramin
Ergamine
Ergotidine
Free histamine
Histamine dihydrochloride
Histamine hydrochloride
HSM
Hydrochloride, histamine
L-Histamin base
L-Histamine
Peremin
Theramine
|
|
30 |
|
Ketotifen |
Approved |
Phase 3 |
|
34580-13-7, 34580-14-8 |
3827 |
Synonyms:
10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (2E)-2-butenedioate (1:1)
116655-74-4
34580-13-7
4-(1-Methyl-4-piperidylidene)-9-hydrobenzo[a]thiopheno[3,2-d][7]annulen-10-one
4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
4-(1-Methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one
4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one
4,9-dihydro-4-(1-Methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one
4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one
AB00053575
AC-15945
AC1L1GSZ
AKOS000541268
Alaway
Alaway (TN)
BAS 00444483
BIDD:GT0509
BPBio1_000575
BRD-K28936863-051-05-8
BRN 3983897
BSPBio_000521
BSPBio_002964
C19H19NOS
CAS-34580-14-8
CHEBI:112957
CHEMBL534
CID3827
D08105
DB00920
DivK1c_000111
EINECS 252-099-7
Fumarate, ketotifen
HC 20-511
HMS2090F16
HSDB 7283
IDI1_000111
KBio1_000111
KBio2_000906
KBio2_003474
KBio2_006042
KBio3_002184
KBioGR_001289
KBioSS_000906
ketotifen
Ketotifen
|
Ketotifen (INN)
Ketotifen [INN:BAN]
Ketotifen fumarate
Ketotifene
Ketotifene [INN-French]
Ketotifene fumarate
Ketotifeno
Ketotifeno [INN-Spanish]
Ketotifenum
Ketotifenum [INN-Latin]
Ketotifin
Ketotiphen
Ketotiphene
L000753
Lopac0_000706
Lopac-K-2628
LS-33820
MolPort-001-933-278
NCGC00015580-01
NCGC00015580-02
NCGC00015580-03
NCGC00015580-09
NCGC00022572-02
NCGC00022572-04
NCGC00022572-05
NINDS_000111
Oprea1_335550
Oprea1_553550
Prestwick0_000371
Prestwick1_000371
Prestwick2_000371
Prestwick3_000371
SPBio_001275
SPBio_002442
Spectrum_000426
Spectrum2_001198
Spectrum3_001382
Spectrum4_000805
Spectrum5_001395
STK048448
STOCK1S-14132
Tocris-0784
UNII-X49220T18G
Zaditen
Zaditor
|
|
31 |
|
Immunoglobulins |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Antibodies |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Immunoglobulins, Intravenous |
|
Phase 2, Phase 3 |
|
|
|
34 |
|
Antibodies, Monoclonal |
|
Phase 2, Phase 3 |
|
|
|
35 |
|
Immunoglobulin G |
|
Phase 2, Phase 3 |
|
|
|
36 |
|
Histamine Antagonists |
|
Phase 3 |
|
|
|
37 |
|
Histamine H1 Antagonists |
|
Phase 3 |
|
|
|
38 |
|
Histamine Phosphate |
|
Phase 3 |
|
51-74-1 |
65513 |
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
39 |
|
Omalizumab |
Approved, Investigational |
Phase 2 |
|
242138-07-4 |
|
Synonyms:
242138-07-4
D05251
Omalizumab
Omalizumab (genetical recombination)
|
Omalizumab (genetical recombination) (JAN)
Omalizumab (USAN/INN)
Xolair
Xolair (TN)
|
|
40 |
|
Losartan |
Approved |
Phase 2 |
|
114798-26-4 |
3961 |
Synonyms:
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
114798-26-4
124750-99-8 (mono-potassium salt)
1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol
2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol
2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole
AC1L1H3Q
BIDD:GT0286
BRD-K76205745-001-02-5
BSPBio_002695
C07072
C22H23ClN6O
CHEBI:6541
CHEMBL191
CID3961
CL23623
Cozaar
D08146
DB00678
DuP 753
DUP 89
DuP-753
HMS1922J13
HMS2093E22
Hyzaar
I14-9710
Jsp001094
KBio2_002193
KBio2_004761
|
KBio2_007329
KBio3_001915
KBioGR_001611
KBioSS_002193
L000351
Lortaan
losartan
Losartan
Losartan (INN)
Losartan [INN:BAN]
Losartan monopotassium salt
losartan potassium
Losartan potassium
LOSARTAN POTASSIUM
Losartic
Losartic (TN)
LS-78746
MK954
MK-954
MolPort-003-666-553
Monopotassium salt, losartan
NCGC00095125-01
NCGC00095125-02
NCGC00095125-03
Oprea1_644635
Potassium, losartan
Salt, losartan monopotassium
SPBio_001893
Spectrum_001713
SPECTRUM1504268
Spectrum2_001677
Spectrum3_000998
Spectrum4_001126
Spectrum5_001466
UNII-JMS50MPO89
|
|
41 |
|
Angiotensin II |
Approved, Investigational |
Phase 2 |
|
4474-91-3, 11128-99-7, 68521-88-0 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-isoleucine-angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-isoleucineangiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
|
Angiotensin-(1-8) octapeptide
Angiotonin
Asp-arg-val-tyr-ile-his-pro-phe
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
42 |
|
Infliximab |
Approved |
Phase 2 |
|
170277-31-3 |
|
Synonyms:
Ig gamma-1 chain C region
Infliximab (genetical recombination)
Infliximab-abda
Infliximab-axxq
|
Infliximab-dyyb
Infliximab-qbtx
Remicade
|
|
43 |
|
tannic acid |
Approved |
Phase 2 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
44 |
|
Benzocaine |
Approved, Investigational |
Phase 2 |
|
94-09-7, 1994-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
|
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
45 |
|
Famotidine |
Approved |
Phase 2 |
|
76824-35-6 |
3325 |
Synonyms:
(1-amino-3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
(1-amino-3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulphamide
(1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide
(1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide
3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide
3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulphonyl)propanimidamide
3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide
3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
76824-35-6
AC-11713
AC1NWASH
AC1Q50E0
AC1Q50E1
Amfamox
Antodine
apo-Famotidine
Apo-Famotidine
Apogastine
Bestidine
BIDD:GT0759
Bio-0739
Blocacid
BPBio1_000098
Brolin
BSPBio_000088
C8H15N7O2S3
CAS-76824-35-6
Cepal
CHEBI:4975
CHEMBL902
CID5702160
Confobos
CPD000058961
Cronol
Cuantin
DB00927
Dibrit 40
Digervin
Dinul
Dipsin
Dispromil
Dispronil
Duovel
Durater
EU-0100497
Evatin
F 6889
F0530
F6889_SIGMA
Fadin
Fadine
Fadyn
Fagastine
Famo
Famocid
Famodar
Famodil
Famodin
Famodine
Famogard
Famonit
Famopsin
Famos
Famosan
Famotal
Famotep
Famotidina
Famotidina [Spanish]
famotidine
Famotidine
Famotidine [USAN:BAN:INN:JAN]
Famotidine hydrochloride
FAMOTIDINE PRESERVATIVE FREE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER
Famotidinum
Famotidinum [Latin]
Famotin
Famovane
Famowal
Famox
Famoxal
Famtac
Famulcer
Fanobel
Fanosin
Fanox
Farmotex
Ferotine
Fibonel
Fluxid
Fudone
Ganor
Gaster
Gastridan
Gastridin
Gastrion
Gastro
Gastrodomina
Gastrofam
Gastropen
Gastrosidin
H2 Bloc
Hacip
HMS1568E10
HMS2051A07
HMS2089I12
|
HS-0054
HSDB 3572
Huberdina
InChI=1/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
Ingastri
Invigan
L 643341
L003830
L013386
Lecedil
Logos
Lopac0_000497
Lopac-F-6889
LS-121117
Mensoma
Midefam
MK 208
MK-208
MLS000028583
MLS000758205
MLS001423994
MolPort-002-557-620
MolPort-003-941-395
Mosul
Motiax
Muclox
Mylanta ar
Mylanta AR
N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine
NCGC00015446-01
NCGC00015446-02
NCGC00015446-03
NCGC00015446-06
NCGC00018276-01
NCGC00018276-02
NCGC00093899-01
NCGC00093899-02
NCGC00093899-03
Neocidine
Nevofam
Notidin
novo-Famotidine
Novo-Famotidine
N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
N-Sulphamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
Nu-Famotidine
Nulceran
Nulcerin
Panalba
PDSP1_000398
PDSP2_000396
Pepcid
PEPCID
Pepcid AC
Pepcid AC Gelcaps
PEPCID COMPLETE
PEPCID PRESERVATIVE FREE
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER
Pepcid RPD
Pepcidac
Pepcidin
Pepcidin pepcidine
Pepcidin Rapitab
Pepcidina
Pepcidine
Pepdif
Pepdine
Pepdul
Pepfamin
Peptan
Peptidin
Peptifam
Pepzan
Prestwick_212
Prestwick2_000104
Prestwick3_000104
Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl)
Purifam
Quamatel
Quamtel
Renapepsa
Restadin
Rogasti
Rubacina
SAM001247033
Sedanium-R
Sigafam
SMR000058961
STK527689
Supertidine
Tairal
Tamin
Tipodex
TL8005267
Topcid
Ulcatif
Ulceprax
Ulcofam
Ulfagel
Ulfam
Ulfamid
Ulfinol
Ulgarine
Vagostal
Weimok
Whitidin
Yamarin
YM 11170
YM-11170
YM-1170
|
|
46 |
|
Loratadine |
Approved, Investigational |
Phase 2 |
|
79794-75-5 |
3957 |
Synonyms:
1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester
1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester
1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester
1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester
4-(8-chloro-5,6-dihydro-11H-benzo(5,6)Cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester
4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester
4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
79794-75-5
AC1L1H3E
AC-2086
Aerotina
Alarin
Alavert
Alavert, Claritin, Loratadine
Alerpriv
Allertidin
Amantadine
Anhissen
BB_SC-2109
Bedix Loratadina
BIDD:GT0198
Biloina
Bonalerg
BRD-K82795137-001-02-3
BRD-K82795137-001-10-6
BSPBio_002300
C22H23ClN2O2
CHEMBL998
Children's Claritin
CID3957
Civeran
Claratyne
Claratyne Cold
Claratyne Decongestant
Clarinase
Clarinase Reperabs
Claritin
Claritin (TN)
Claritin D
Claritin Hives Relief
Claritin Hives Relief Reditab
Claritin reditab
Claritin Reditabs
Claritine
Clarityn
Clarityne
Clarityne Dy Repetabs
Clarityne-D
Clarium
CPD000058255
Cronopen
D00364
D017336
DB00455
DivK1c_000792
Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate
ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate
EU-0100680
Flonidan
Fristamin
Histaloran
HMS2051G11
HMS2090O18
HMS2093I15
HMS502H14
HSDB 3578
I14-0747
IDI1_000792
KBio1_000792
KBio2_001976
KBio2_004544
KBio2_007112
KBio3_001520
KBioGR_000693
KBioSS_001976
Klaritin
L 9664
L000667
L0223
L9664_SIGMA
Lergy
Lertamine
|
Lesidas
Lisino
Lopac0_000680
Lopac-L-9664
Loracert
Loradex
Loradif
Loranox
Lorantis
Lorastine
Loratadina
Loratadina [Spanish]
loratadine
Loratadine
Loratadine (JAN/USAN/INN)
Loratadine [USAN:BAN:INN]
Loratadine Redidose
Loratadine wyeth brand
Loratadine Wyeth Brand
Loratadinum
Loratadinum [Latin]
Loratidine
Loratyne
Loraver
Lorfast
Loritine
Lowadina
LS-114660
MLS000069647
MLS000758260
MLS001148466
MolPort-002-507-846
NCGC00015619-01
NCGC00015619-02
NCGC00015619-06
NCGC00015619-10
NCGC00023125-02
NCGC00023125-04
NCGC00023125-05
NCGC00023125-06
NCGC00023125-07
NCI60_041473
NINDS_000792
NSC721075
Nularef
Oprea1_027965
Optimin
Polaratyne
Pylor
Restamine
Rhinase
Rinomex
Roletra
S1358_Selleck
SAM001246987
Sanelor
Sch 29851
Sch29851
Sch-29851
Sensibit
Sinhistan Dy
SMR000058255
Sohotin
SPBio_001548
Spectrum_001496
SPECTRUM1503712
Spectrum2_001584
Spectrum3_000740
Spectrum4_000177
Spectrum5_001650
STK574925
Tadine
Talorat Dy
TL8005389
Tocris-1944
UNII-7AJO3BO7QN
Velodan
Versal
Wyeth brand OF loratadine
Wyeth Brand of Loratadine
Zeos
ZINC00537931
|
|
47 |
|
Bethanechol |
Approved |
Phase 2 |
|
674-38-4 |
2370 |
Synonyms:
(2-hydroxypropyl)trimethylammonium carbamate
(2-Hydroxypropyl)trimethylammonium carbamate
(2-Hydroxypropyl)trimethylammonium carbamic acid
1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl- (9CI)
2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium
2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium
2-(Carbamoyloxy)-N,N,N-trimethylpropan-1-aminium
2-carbamoyloxypropyl(trimethyl)azanium
2-carbamoyloxypropyl-trimethylazanium
2-Carbamoyloxypropyl-trimethylazanium
590-63-6 (chloride)
674-38-4
AB00053794
AC1L1DJ2
Amidopropyldimethylbetaine
Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester)
Besacholine
beta-Methyl carbachol chloride
Bethaine choline chloride
bethanechol
Bethanechol
Bethanechol chloride
Bethanecol
BPBio1_001196
BRN 1773706
BSPBio_001086
BSPBio_001902
BTC
C06850
C7H17N2O2
Carbamoyl-beta-methylcholine
Carbamoyl-b-methylcholine
carbamoyl-β-methylcholine
Carbamoyl-β-methylcholine
Carbamyl-beta-methylcholine
Carbamyl-b-methylcholine
Carbamylmethylcholine chloride
carbamyl-β-methylcholine
Carbamyl-β-methylcholine
CHEBI:3084
CHEMBL1482
Chloride, bethanechol
CID2370
DB01019
DivK1c_000179
|
Duvoid
Glenwood brand OF bethanechol chloride
Hamilton brand OF bethanechol chloride
Hermes, myo
HMS2089I08
IDI1_000179
KBio1_000179
KBio2_000504
KBio2_003072
KBio2_005640
KBio3_001402
KBioGR_000690
KBioSS_000504
Lopac0_000304
LS-18498
myo Hermes
Myocholine
Myotonachol
Myotonine
Myotonine chloride
NCGC00015245-06
NCGC00089770-02
NCGC00163217-01
NINDS_000179
Organon brand OF bethanechol chloride
Pharmascience brand OF bethanechol chloride
PMS Bethanechol chloride
PMSBethanechol chloride
PMS-Bethanechol chloride
Prestwick0_001073
Prestwick1_001073
Prestwick2_001073
Prestwick3_001073
Roberts brand OF bethanechol chloride
SPBio_000204
SPBio_002993
Spectrum_000084
Spectrum2_000132
Spectrum3_000311
Spectrum4_000255
Spectrum5_000892
UNII-004F72P8F4
Urabeth
Urocarb
|
|
48 |
|
mometasone furoate |
Approved, Investigational, Vet_approved |
Phase 2 |
|
83919-23-7 |
|
Synonyms:
|
Mometasone furoate anhydrous
|
|
49 |
|
Trichostatin A |
Experimental |
Phase 2 |
|
58880-19-6 |
|
Synonyms:
|
50 |
|
Vasoconstrictor Agents |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 162)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis |
Completed |
NCT02371941 |
Phase 4 |
oral cromolyn sodium;Placebo |
2 |
Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis |
Completed |
NCT02019758 |
Phase 4 |
Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler |
3 |
COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) |
Completed |
NCT01846962 |
Phase 4 |
Budesonide;Fluticasone;Oral Viscous Budesonide (OVB) |
4 |
Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE) |
Recruiting |
NCT04149470 |
Phase 4 |
Omeprazole 20mg BID |
5 |
Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis |
Recruiting |
NCT03781596 |
Phase 4 |
Fluticasone;Omeprazole;Placebo oral capsule |
6 |
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors |
Terminated |
NCT01404832 |
Phase 4 |
Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms |
7 |
Proton Pump Inhibitor (PPI's) and Selective Serotonin Reuptake Inhibitor Therapy (SSRI's) for the Management of Non Cardiac Chest Pain (NCCP) |
Terminated |
NCT02825342 |
Phase 4 |
Citalopram |
8 |
Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial |
Completed |
NCT00266578 |
Phase 3 |
Fluticasone Propionate |
9 |
An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years |
Completed |
NCT00538434 |
Phase 2, Phase 3 |
|
10 |
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study |
Completed |
NCT02605837 |
Phase 3 |
Oral Budesonide Suspension (OBS);Placebo |
11 |
Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis |
Completed |
NCT02434029 |
Phase 3 |
Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily |
12 |
An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002 |
Completed |
NCT00635089 |
Phase 3 |
reslizumab |
13 |
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE) |
Completed |
NCT02736409 |
Phase 3 |
Oral Budesonide Suspension (OBS);Placebo |
14 |
Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids |
Completed |
NCT02610816 |
Phase 2, Phase 3 |
Fluticasone Propionate, 800 mcg twice daily (post 4FED failure) |
15 |
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis |
Completed |
NCT00728481 |
Phase 2, Phase 3 |
Esomeprazole;Budesonide |
16 |
Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial |
Completed |
NCT02778867 |
Phase 2, Phase 3 |
Fluticasone Propionate, 880 mcg twice daily (after 6FED failure) |
17 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) |
Recruiting |
NCT04322604 |
Phase 3 |
antolimab (AK002) |
18 |
A Double-Blind, Placebo-controlled Clinical Trial to Evaluate Efficacy of Benralizumab in Subjects With Eosinophilic Gastritis |
Recruiting |
NCT03473977 |
Phase 2, Phase 3 |
|
19 |
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Antolimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis |
Recruiting |
NCT04322708 |
Phase 2, Phase 3 |
antolimab (AK002) |
20 |
Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects With Eosinophilic Esophagitis |
Recruiting |
NCT04281108 |
Phase 3 |
APT-1011;Placebo oral tablet |
21 |
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) |
Recruiting |
NCT03633617 |
Phase 3 |
Dupilumab;Placebo |
22 |
Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia |
Recruiting |
NCT02484248 |
Phase 3 |
Ketotifen;Placebo |
23 |
Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis |
Active, not recruiting |
NCT02493335 |
Phase 3 |
Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily |
24 |
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) |
Active, not recruiting |
NCT03245840 |
Phase 3 |
Budesonide oral suspension |
25 |
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis |
Not yet recruiting |
NCT04394351 |
Phase 3 |
Dupilumab;Matching Placebo |
26 |
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone |
Withdrawn |
NCT01702701 |
Phase 3 |
Montelukast;Fluticasone |
27 |
A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder. |
Unknown status |
NCT01808196 |
Phase 2 |
Losartan Potassium |
28 |
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis |
Completed |
NCT03496571 |
Phase 2 |
AK002 |
29 |
Pilot Study of Omalizumab in Eosinophilic Gastroenteritis |
Completed |
NCT00084097 |
Phase 2 |
Omalizumab |
30 |
A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes |
Completed |
NCT00266565 |
Phase 1, Phase 2 |
Mepolizumab |
31 |
A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis |
Completed |
NCT00426283 |
Phase 2 |
Flovent |
32 |
A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis |
Completed |
NCT01056783 |
Phase 2 |
OC000459;Placebo |
33 |
A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE) |
Completed |
NCT01022970 |
Phase 2 |
QAX576 placebo;QAX576 |
34 |
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis |
Completed |
NCT02098473 |
Phase 2 |
RPC4046;Placebo |
35 |
Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial |
Completed |
NCT00638456 |
Phase 2 |
Budesonide plus Prevacid;placebo plus Prevacid |
36 |
Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents |
Completed |
NCT00762073 |
Phase 2 |
budesonide;placebo |
37 |
A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children |
Completed |
NCT02579876 |
Phase 2 |
Viaskin Milk 500 mcg;Viaskin Placebo |
38 |
A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219) |
Completed |
NCT00358449 |
Phase 2 |
mepolizumab |
39 |
A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis |
Completed |
NCT02379052 |
Phase 2 |
Dupilumab;Placebo |
40 |
Double-blind, Double-dummy, Randomized, Placebo-controlled, Phase IIa Study on the Efficacy and Tolerability of a 14-day Treatment With Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Patients With Eosinophilic Esophagitis |
Completed |
NCT02280616 |
Phase 2 |
low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo |
41 |
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension |
Completed |
NCT01642212 |
Phase 2 |
Oral Budesonide Suspension (MB-9);Placebo |
42 |
A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder |
Completed |
NCT03029091 |
Phase 2 |
Losartan Potassium |
43 |
Budesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment Study |
Completed |
NCT00271349 |
Phase 2 |
Budesonide |
44 |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE) |
Completed |
NCT01386112 |
Phase 1, Phase 2 |
EUR-1100;placebo |
45 |
A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis |
Completed |
NCT00275561 |
Phase 2 |
Fluticasone;Placebo |
46 |
Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis |
Completed |
NCT00123656 |
Phase 2 |
esomeprazole;fluticasone |
47 |
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab |
Completed |
NCT00123630 |
Phase 2 |
omalizumab;Placebo |
48 |
Phase 2 Proof-of-Concept Study to Analyze the Efficacy of in TNF-Alpha Blockade in Adult Patients With Severe, Corticosteroid-Dependent Eosinophilic Esophagitis |
Completed |
NCT00523354 |
Phase 2 |
Infliximab |
49 |
A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary Evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous Anti-human Interleukin-5 (Mepolizumab, 750mg and 1500mg) in the Treatment of Eosinophilic Oesophagitis in Adults |
Completed |
NCT00274703 |
Phase 2 |
mepolizumab |
50 |
Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. |
Completed |
NCT01705795 |
Phase 2 |
Mepolizumab (a-IL-5 antibody);Placebo |
|